

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20281
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/937,215	09/24/2001	Se Yong Lee	1599-0206P	6757
2292 75	590 04/03/2003			
BIRCH STEWART KOLASCH & BIRCH PO BOX 747			EXAMINER	
			PATTERSON, CHARLES L JR	
FALLS CHUR	FALLS CHURCH, VA 22040-0747			·
			ART UNIT	PAPER NUMBER
			1652	7
		DATE MAILED: 04/03/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		•				
		09/937,215	LEE ET AL.			
	Office Action Summary	Examiner	Art Unit			
	Th. MAILING DATE of this communication and	Charles L. Patterson, Jr.	1652			
Th MAILING DATE of this communication appears on the cover sheet with the corr spondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1)⊠	Responsive to communication(s) filed on 21 May 2002.					
2a) <u></u> □	This action is FINAL . 2b)⊠ This	s action is non-final.	1			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) 🛛 (Claim(s) <u>1-9</u> is/are pending in the application.					
4	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) 🗌 (Claim(s) is/are allowed.					
6)⊠ (⊠ Claim(s) <u>1,2 and 5-9</u> is/are rejected.					
7) 🛛 (Claim(s) <u>3 and 4</u> is/are objected to.					
	Claim(s) are subject to restriction and/or	election requirement.				
Application	•					
	he specification is objected to by the Examiner					
10)⊠ The drawing(s) filed on <u>24 September 2001</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
	1. Certified copies of the priority documents have been received.					
2	Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received.						
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)			

Application/Control Number: 09/937,215

Art Unit: 1652

Claims 1 and 2 do not meet the requirements of 37 CFR 1.821(d) in that the sequences are not identified with "SEQ ID NO:". For the purposes of this action it is presumed that claim 1 should be SEQ ID NO:2 and claim 2 should be SEQ ID NO:1. It is not necessary to repeat the sequence in the body of the claims. Also, sequences in the specification such as on pages 3-8 must also be labeled.

The disclosure is objected to because of the following informalities:

The first column of Figure 1 is not identified in either the Brief

Description on pages 9-10 or on page 14. This should be done, preferably in the Brief Description on page 10.

On page 10, apparently the brief descriptions of Figure 5 and 6 have been reversed. Similarly, "Example 7" on page 18 should apparently refer to Figure 6 and "Example 8" should refer to Figure 5.

Appropriate correction is required.

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 1, 2 and 9 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. A patent claim must indicate the intervention of the "hand of man". These claims read on the enzyme, gene or organism as they occur in nature. Adding "isolated" or some similar recitation would overcome the instant rejection.

Application/Control Number: 09/937,215

Art Unit: 1652

Claims 5-6 and 8-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 5 is incorrect in the recitation of "E. coli", which should be "E. coli".

Claim 6 is indefinite in the recitation of "transformant", which does not have antecedent basis in claim 5.

Claim 8 is confusing in the recitation of "crushing" and "crushed" on lines 1 and 2. "Crushing" a bacterial cell will not lyse it as "crushing" could entail simply pressing down on the culture with a hard object. Some other word such as "lysing", "breaking" or "sonicating" as in the Brief Description of Figure 3 and one page 13, line 31, should be used.

Claim 9 is confusing in the recitation of "novel microorganism".

Whether the microorganism is novel or not is yet to be determined in the examination of this patent application.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 9 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The instant claims require the presence *Pseudomonas strutzeri* CJ38. It is not clear that all of the requirements of 37 CFR 1.801-1.809 as to deposit conditions and availability upon issuance of a U.S. patent have been met.

Application/Control Number: 09/937,215

Art Unit: 1652

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 7 and 9 are rejected under 35 U.S.C. 102(b) as being anticipated by either of Nishimoto, et al. (AB, A or U) or Ohguchi, et al. (V). The instant references each teach the isolation of a trehalose synthase enzyme from a *Pseudomonas*. It is maintained that the enzyme taught by the instant references is the same as that of claim 1 and 7 and the *Pseudomonas* is the same as in claim 9, absent convincing proof to the contrary. Sequencing an enzyme does not of itself lend any patentability to the enzyme per se.

Claims 3 and 4 are objected to as being dependent upon a rejected base claim.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charles L. Patterson, Jr., PhD, whose telephone number is 703-308-1834. The examiner can normally be reached on Monday - Friday, 7:30-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy can be reached on 703-308-3804. The fax phone number is 703-308-4242.

Application/Control Number: 09/937,215 Page 5

Art Unit: 1652

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Charles L. Patterson, Jr.

Primary Examiner Art Unit 1652

Patterson March 28, 2003